ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "combination therapies"

  • Abstract Number: 2324 • 2013 ACR/ARHP Annual Meeting

    Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient

    Jie Zhang1, Fenglong Xie2, Elizabeth S. Delzell3, Huifeng Yun3, James Lewis4, Kevin Haynes5, Lang Chen6 and Jeffrey R. Curtis7, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, 6Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama at Birmingham, Birmingham, AL

    Persistence on Biologics is Associated with Concomitant Methotrexate Use among Rheumatoid Arthritis Patient Background/Purpose: Concomitant methotrexate (MTX) is associated with improved treatment efficacy in randomized controlled…
  • Abstract Number: 2283 • 2013 ACR/ARHP Annual Meeting

    The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes

    Laurent Chanroux, Katrina Johnson and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom

    Background/Purpose: The aim of our study is to understand whether the use of biologic monotherapy among rheumatoid arthritis (RA) patients is increasing and whether this…
  • Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting

    Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)

    Boulos Haraoui1, J. Carter Thorne2, Edward C. Keystone3, Melanie Poulin-Costello4, Eric Trottier5, Andrew Vieira6 and Janet E. Pope7, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 4Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, 5Medical Communications, Amgen Canada, Mississauga, ON, Canada, 6Amgen Canada Inc., Mississauga, ON, Canada, 7St Joseph Health Care, London, ON, Canada

    Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
  • Abstract Number: 1424 • 2013 ACR/ARHP Annual Meeting

    Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare

    Jonathan Kruger1, Ted R. Mikuls2 and Grant W. Cannon3, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT

    Background/Purpose: A limited number of rheumatoid arthritis (RA) patients are managed with a single disease-modifying anti-rheumatic drug (DMARD).   Previous studies have suggested that DMARD naïve…
  • Abstract Number: 1348 • 2013 ACR/ARHP Annual Meeting

    Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit?

    I.M. Markusse1, K.H. Han2, A.J. Peeters3, H.K Ronday4, P.J.S.M. Kerstens5, T.W.J. Huizinga1, W.F. Lems6 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 4Rheumatology, Haga Hospital, The Hague, Netherlands, 5Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 6Rheumatology, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Initial combination therapy has proven to be effective in early rheumatoid arthritis (RA) patients. To determine which patients benefit from initial combination therapy.  Methods:…
  • Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting

    Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial

    Adrian Levitsky1, Kristina Forslind2,3 and Ronald F. van Vollenhoven4, 1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 2Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund, Sweden, 3Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, 4Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…
  • Abstract Number: 282 • 2013 ACR/ARHP Annual Meeting

    Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy

    Caroline Y Chang1, Rika Meyer2 and Andreas Reiff1, 1Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 2Children's Hospital Los Angeles, Los Angeles, CA

    Background/Purpose: Combination therapy of tumor necrosis factor inhibitors (TNFi) and methotrexate (MTX) is a well-established treatment that has dramatically changed outcomes in Juvenile Idiopathic Arthritis…
  • Abstract Number: L3 • 2013 ACR/ARHP Annual Meeting

    A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis

    MC Genovese1, Ronald van Vollenhoven2, Bradley J. Bloom3, John G. Jiang3 and Nils Kinnman4, 1Stanford University, Palo Alto, CA, 2Karolinska Institute, Stockholm, Sweden, 3Vertex Pharmaceuticals Incorporated, Cambridge, MA, 4Vertex Pharmaceuticals Incorporated, Eysins, Switzerland

    Background/Purpose: VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). The objective of this 24-week, randomized, placebo-controlled, double-blind,…
  • Abstract Number: 345 • 2012 ACR/ARHP Annual Meeting

    Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis – Validation in a Murine Collagen Induced Arthritis Model

    Gurkirpal Singh1, Robinson Vidva2, Prashant Nair2, Saumya Radhakrishnan2, Pradeep Fernandes2, Taher Abbasi2, Canio Refino3, Jay Dela Cruz3 and Shireen Vali2, 1Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, 2CellWorks Group, Saratoga, CA, 3InTouch Bio, Alameda, CA

    Background/Purpose: Rheumatoid Arthritis (RA) involves complex interactions of multiple cell systems, cytokines and mediators, and interlinked signaling.  While molecularly-targeted therapies manipulate specific interactions, it is…
  • Abstract Number: 342 • 2012 ACR/ARHP Annual Meeting

    Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model

    Shireen Vali1, Canio Refino2, Jay Dela Cruz2, Robinson Vidva1, Prashant Nair1, Saumya Radhakrishnan1, Pradeep Fernandes1, Taher Abbasi1 and Gurkirpal Singh3, 1CellWorks Group, Saratoga, CA, 2InTouch Bio, Alameda, CA, 3Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: Rheumatoid Arthritis (RA) involves a complex interaction of multiple cell systems, cytokines and mediators. We recently developed a predictive software-based mathematical model that emulates…
  • Abstract Number: 358 • 2012 ACR/ARHP Annual Meeting

    Six Months of an Attenuated Cobra Regimen (‘COBRA-light’) Is Clinically Noninferior to the Original Cobra Regimen: An Open-Label Randomized Trial in Early Rheumatoid Arthritis

    Debby den Uyl1, Marieke M. ter Wee1, Maarten Boers2, Alexandre Voskuyl3, P.J.S.M. Kerstens4, Mike T. Nurmohamed5, Hennie G. Raterman1, Dirkjan van Schaardenburg5, N. van Dillen4, B.a.C Dijkmans1 and W.F. Lems1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, 3Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, Reade | Jan van Breemen Research Institute, Amsterdam, Netherlands, 5Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    Background/Purpose: Early, intensive treatment of rheumatoid arthritis (RA) with combination therapy (COBRA therapy) considerably lowers disease activity and suppresses radiological progression. Although proven to be…
  • Abstract Number: 354 • 2012 ACR/ARHP Annual Meeting

    Delayed Onset of Hepatitis and/or Neutropenia in Patients with Rheumatoid Arthritis Treated with Combination Therapy of Methotrexate and Leflunomide

    Seung Won Choi1, Ji Seon Oh1, You Jae Kim2, Bon San Koo2, Min Wook So2, Yong-Gil Kim2, Chang-Keun Lee2 and Bin Yoo2, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

    Background/Purpose: The adverse effects of combination therapy of methotrexate (MTX) and leflunomide (LEF) have been reported in many studies. Because combination of various doses of…
  • Abstract Number: 353 • 2012 ACR/ARHP Annual Meeting

    The Effect of Combination Therapy and Prednisolone On Haemostatic Markers in Rheumatoid Arthritis

    Inge A.M. van den Oever1, Danka J.F. Stuijver2, Debby den Uyl3, Bregje van Zaane4, Marieke M. ter Wee5, Willem F. Lems5, Dirkjan van Schaardenburg1, Joost C.M. Meijers4, Victor E.A. Gerdes4 and M. T. Nurmohamed6, 1Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU University medical centre, Amsterdam, Netherlands, 4Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands, 5Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 6VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands

    Background/Purpose: There is accumulating evidence that rheumatoid arthritis (RA) should be considered as prothrombotic state, explaining the increased risk of thromboembolic events. Suppressing inflammation could…
  • Abstract Number: 453 • 2012 ACR/ARHP Annual Meeting

    Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose

    Susanna Proudman1, Llew Spargo1, Cindy Hall1, Leah McWilliams1, Anita Lee1, Maureen Rischmueller2, Robert Gibson3, Michael James1 and Leslie G. Cleland1, 1Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 2Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, 3University of Adelaide, Adelaide, Australia

    Background/Purpose: The symptomatic benefit and NSAID-sparing effects of fish oil (FO) in RA are well known but effects on disease outcomes are less well established,…
  • Abstract Number: 1287 • 2012 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti-Rheumatic Drugs Before Biologicals

    James R. O'Dell1, Ted R. Mikuls2, Thomas Taylor3, Vandana Ahluwalia4, Mary Brophy5, Stuart Warren6, Robert Lew5, Ciaran Phibbs7, Aslam H. Anis8, Amy C. Cannella9, Gary A. Kunkel10, Alan R. Erickson2, Edward Keystone11 and the CSP551 RACAT Research Group12, 1Dept of Internal Medicine, Omaha VA and University of Nebraska Medical Center, Omaha, NE, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3VA Medical Center, White River Junction, VT, 4William Osler Health Center, Brampton, ON, Canada, 5VA Boston Heathcare System, Boston, MA, 6VA CSP Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, 7Health Economics Resource Center (152), Palo Alto VA Health Care System, Menlo Park, CA, 8Population and Public Health, Univ of British Columbia, Vancouver, BC, Canada, 9Divison of Rheumatology, Omaha VA and University of Nebraska Medical Center, Omaha, NE, 10Div of Rheumatology, George Wahlen Veterans Affairs Medical Center, Salt Lake City, UT, 11University of Toronto, Toronto, ON, Canada, 12Boston, MA

    Background/Purpose: Double-blind placebo controlled randomized trials have demonstrated the efficacy of 15 different therapies in RA patients with active disease despite methotrexate (MTX). No blinded…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.